Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies

Abstract Background Pyrotinib, a novel irreversible tyrosine kinase inhibitor (TKI), has demonstrated promising antitumor activity to improve the overall response rate and progression-free survival (PFS) in patients with HER2-positive metastatic breast cancer (MBC). However, the survival data of pyr...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiuwen Guan (Author), Fei Ma (Author), Qiao Li (Author), Shanshan Chen (Author), Bo Lan (Author), Ying Fan (Author), Jiayu Wang (Author), Yang Luo (Author), Ruigang Cai (Author), Pin Zhang (Author), Qing Li (Author), Binghe Xu (Author)
Format: Book
Published: BMC, 2023-02-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available